Grail to partner with Premier

By LabPulse.com staff writers

January 10, 2022 -- Grail has signed a collaborative agreement with Premier to use that company's PINC AI technology and services platform to expand patient access to Grail's Galleri early cancer detection blood test.

PINC AI will offer clinicians decision support for assessing whether patients at elevated cancer risk could benefit from Galleri through an alert function, Grail said. Community Health Network of Indianapolis is the first health system that will pilot the service.

Galleri can detect more than 50 types of cancer through a blood sample, according to Grail. It is intended to be used in addition to recommended cancer screening exams.

Illumina appoints Ragusa as CEO of Grail
Illumina has appointed Bob Ragusa as CEO of Grail, which currently operates as a separate and independent unit of Illumina after its August acquisition.
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...
Grail teams with Quest on blood test for early cancer detection
Cancer diagnostics startup Grail has signed Quest Diagnostics to provide phlebotomy services for its upcoming Galleri multicancer early detection blood...
Grail to collaborate with top companies for MRD detection
Cancer diagnostics startup Grail has announced collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate the ability of Grail's methylation-based...
Grail raises $390M for multicancer liquid biopsy
Menlo Park, CA-based startup Grail has raised an additional $390 million to advance its multicancer blood test, which is being validated for the...

Copyright © 2022 LabPulse.com

Last Updated ls 1/10/2022 3:31:49 PM